Trial Profile
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study To Confirm Dose Responsiveness Following 12 Weeks Of The Administration Of CP-690550 (5 Doses) Or Placebo In Subjects With Active Rheumatoid Arthritis Inadequately Responding To At Least 1 DMARD
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 09 Nov 2021
Price :
$35
*
At a glance
- Drugs Tofacitinib (Primary)
- Indications Rheumatoid arthritis
- Focus Therapeutic Use
- Sponsors Pfizer
- 12 Sep 2019 Results characterizing the relationship between tofacitinib dose and efficacy, as measured by American College of Rheumatology (ACR) response rates, and comparing this between Japanese and Western patients with RA using data from 2 double blind studies (NCT00687193 and NCT00550446) published in the Journal of Clinical Pharmacology
- 15 Jun 2019 Results of post hoc pooled analysis evaluating whether treatment of RA with tofacitinib + MTX or GC suppresses IFN pathway proteins to a greater extent than treatment with tofacitinib monotherapy (NCT00687193, NCT00847613, NCT01039688) presented at the 20th Annual Congress of the European League Against Rheumatism
- 16 Jun 2018 Results of pooled data from 4 Phase 2 trials (NCT00413660; NCT00550446; NCT00603512; NCT00687193) and 5 Phase 3 randomised, double-blind, placebo-controlled trials (ORAL Scan [NCT00847613]; ORAL Solo [NCT00814307]; ORAL Sync [NCT00856544]; ORAL Standard [NCT00853385]; ORAL Step [NCT00960440]), were presented at the 19th Annual Congress of the European League Against Rheumatism.